• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

美国州级药品定价透明度法律分析。

Analysis of State-Level Drug Pricing Transparency Laws in the United States.

机构信息

Sol Price School of Public Policy, University of Southern California, Los Angeles.

Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles.

出版信息

JAMA Netw Open. 2019 Sep 4;2(9):e1912104. doi: 10.1001/jamanetworkopen.2019.12104.

DOI:10.1001/jamanetworkopen.2019.12104
PMID:31553467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6763978/
Abstract

This cross-sectional study examines state drug pricing transparency laws enacted to increase supply chain price transparency in the United States.

摘要

这项横断面研究考察了美国为提高供应链价格透明度而颁布的州药品定价透明度法。

相似文献

1
Analysis of State-Level Drug Pricing Transparency Laws in the United States.美国州级药品定价透明度法律分析。
JAMA Netw Open. 2019 Sep 4;2(9):e1912104. doi: 10.1001/jamanetworkopen.2019.12104.
2
Generic Drugs in the United States: Policies to Address Pricing and Competition.美国的仿制药：解决定价和竞争问题的政策。
Clin Pharmacol Ther. 2019 Feb;105(2):329-337. doi: 10.1002/cpt.1314. Epub 2019 Jan 10.
3
Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System.药品定价透明度重要吗？审视巴西的公共采购系统。
Global Health. 2015 Aug 4;11:34. doi: 10.1186/s12992-015-0118-8.
4
States on the Front Line: Addressing America's Drug Pricing Problem.处于前沿的各州：应对美国的药品定价问题。
J Leg Med. 2019 Apr-Jun;39(2):81-93. doi: 10.1080/01947648.2019.1645544.
5
The Economics of Indication-Based Drug Pricing.基于适应症的药品定价经济学
N Engl J Med. 2017 Jul 13;377(2):103-106. doi: 10.1056/NEJMp1705035.
6
The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs.联邦制的负担：各州控制处方药成本尝试面临的挑战。
J Leg Med. 2019 Apr-Jun;39(2):95-120. doi: 10.1080/01947648.2019.1645541.
7
Laws fail to slow gray market. Concerns raised over secondary drug distributors.法律未能减缓灰色市场。人们对药品二级经销商表示担忧。
Mod Healthc. 2011 Oct 3;41(40):14.
8
Pharmaceuticals and Medical Devices: Cost Savings.药品和医疗器械：成本节约。
Issue Brief Health Policy Track Serv. 2017 Dec 26;2017:1-31.
9
Dormant Commerce Clause--Extraterritoriality Doctrine--Fourth Circuit Invalidates Maryland Statute Regulating Price Gouging in the Sale Of Generic Drugs.--Association for Accessible Medicines v. Frosh, 887 F.3d 664 (4th Cir. 2018).休眠商业条款——域外效力原则——第四巡回上诉法院判定马里兰州一项规范非专利药品销售中哄抬物价行为的法规无效。——可及药品协会诉弗罗什案，887 F.3d 664（第四巡回上诉法院，2018年）
Harv Law Rev. 2019 Apr;132(6):1748-55.
10
The Pay-Twice Critique, Government Funding, and Reasonable Pricing Clauses.双重付费批评、政府资金与合理定价条款
J Leg Med. 2019 Apr-Jun;39(2):177-211. doi: 10.1080/01947648.2019.1648942.

引用本文的文献

1
Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review.关于潜在创新型卫生技术的价格决定因素及定价政策：一项范围综述
Eur J Health Econ. 2025 Sep 6. doi: 10.1007/s10198-025-01834-y.
2
The high costs of anticancer therapies in the USA: challenges, opportunities and progress.美国抗癌疗法的高昂成本：挑战、机遇和进展。
Nat Rev Clin Oncol. 2024 Dec;21(12):888-899. doi: 10.1038/s41571-024-00948-1. Epub 2024 Oct 4.
3
On the motivation for pharmaceutical manufacturer coupons: Brand loyalty or customer acquisition?关于制药商优惠券的动机：品牌忠诚度还是客户获取？
Health Serv Res. 2025 Apr;60(2):e14379. doi: 10.1111/1475-6773.14379. Epub 2024 Sep 1.
4
Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications.从胰岛素中吸取的教训：制定负担得起的糖尿病和肥胖症药物的政策处方。
Diabetes Care. 2024 Aug 1;47(8):1246-1256. doi: 10.2337/dci23-0042.
5
Implementing real-time prescription benefit tools: Early experiences from 5 academic medical centers.实施实时处方福利工具：5 所学术医学中心的早期经验。
Healthc (Amst). 2023 Jun;11(2):100689. doi: 10.1016/j.hjdsi.2023.100689. Epub 2023 Mar 28.
6
Affordable Prices Without Threatening the Oncological R&D Pipeline-An Economic Experiment on Transparency in Price Negotiations.平价而不危及肿瘤研发管线——价格谈判透明度的经济试验。
Cancer Res Commun. 2022 Jan 27;2(1):49-57. doi: 10.1158/2767-9764.CRC-21-0031. eCollection 2022 Jan.
7
Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018.2014 年至 2018 年期间，美国制造商、批发商、药品福利经理、药店和健康计划捕获的胰岛素净支出份额估计。
JAMA Health Forum. 2021 Nov 5;2(11):e213409. doi: 10.1001/jamahealthforum.2021.3409. eCollection 2021 Nov.
8
Bending Versus Transforming the Drug Cost Curve: A Matter of Political Will.弯曲与改变药品费用曲线：政治意愿的问题。
Cancer J. 2020 Jul/Aug;26(4):304-310. doi: 10.1097/PPO.0000000000000458.
9
Errors in the Supplement.补编中的错误。
JAMA Netw Open. 2019 Oct 2;2(10):e1915280. doi: 10.1001/jamanetworkopen.2019.15280.

本文引用的文献

1
The States as Important Laboratories for Federal Prescription Drug Cost-Containment Efforts.作为联邦处方药成本控制努力重要试验场的各州。
JAMA. 2019 Apr 23;321(16):1561-1562. doi: 10.1001/jama.2019.2189.
2
Insulin Access and Affordability Working Group: Conclusions and Recommendations.胰岛素可及性与可负担性工作组：结论与建议
Diabetes Care. 2018 Jun;41(6):1299-1311. doi: 10.2337/dci18-0019. Epub 2018 May 8.
3
State Initiatives to Control Medication Costs--Can Transparency Legislation Help?控制药物成本的国家举措——透明度立法能有所帮助吗？
N Engl J Med. 2016 Jun 16;374(24):2301-4. doi: 10.1056/NEJMp1605100.